Anthropic launches Claude Science

The most important thing to understand about Claude Science is what it is not: it is not a new biology model. It is a workbench built on existing Claude models, which Anthropic explicitly ranks alongside Claude Code and Claude Cowork as a flagship product ^[2]. The architecture is pure orchestration. A generalist coordinating agent carries 60-plus curated skills and dispatches specialist agents for genomics, single-cell, proteomics, structural biology, and cheminformatics, while a separate reviewer agent validates outputs during pipeline execution - flagging incorrect citations, numbers it cannot trace, and figures that do not match their underlying code ^[5]. This is the same move that made Claude Code work: wrap capable models in a scaffold of tools, skills, and self-checking, then let natural language drive the whole thing. Claude Science translates intent into operational action so researchers avoid manually configuring predictive models, standing up network endpoints, or managing software environments ^[4]. It reaches out to 60-plus scientific databases - UniProt, PDB, Ensembl, Reactome, ClinVar, ChEMBL, GEO - and calls NVIDIA's BioNeMo Agent Toolkit to run Evo 2, Boltz-2, and OpenFold3 as skills ^[4]. The competitive framing writes itself as a model race, but the real story is an orchestration layer, and that distinction is exactly what the sharpest skeptics have latched onto.

The launch came with an unusual second announcement: Anthropic will run its own internal drug discovery program, focused on rare and neglected diseases that big pharma skips for profitability reasons ^[6]. A demo showed Claude Science autonomously identifying drug candidates for phenylketonuria, and the humanitarian pitch is real - but so is the dogfooding logic. Running a real lab lets Anthropic validate the product on live research and learn what pharma workflows actually demand ^[6]. This is vertical integration, and it did not happen by accident. In April 2026 Anthropic paid roughly $400 million, all-stock, for Coefficient Bio, a stealth AI-native biotech with fewer than ten employees ^[8]. That acquisition folded ex-Genentech researchers Nathan Frey and Samuel Stanton into Anthropic's life sciences group and seeded the drug-discovery capability ^[7]. The through-line from a $400M acqui-hire to an internal neglected-disease lab to a flagship workbench is a deliberate bet that biology is where AI most benefits humanity ^[2]. Amodei, for his part, keeps the caveat in view: he conceded the whole thing may not work out, and that Anthropic is only seeing early signs ^[3].

For scientists, the make-or-break question with any AI system is whether you can trust and defend the output. Claude Science's answer is that every result carries an auditable, reproducible history - the exact code, the environment, a plain-language description, and the full message history of how it was made, so results can be validated and reproduced ^[1]. That audit trail is reinforced at runtime by the reviewer agent that flags untraceable citations and numbers and figures that do not match their code ^[5]. Two workflow features push this further. Session forking lets researchers branch at any point to compare analytical approaches without losing the original thread ^[1]. And compute scales elastically from a laptop to HPC clusters over SSH or to on-demand GPUs via Modal, from a single GPU to hundreds ^[5]. The payoff early users describe is dramatic: at the Allen Institute a literature review that took roughly two years was cut to a fraction, and UCSF reported genomic analysis running about ten times faster ^[1]. Native rendering of 3D protein structures, genome tracks, and chemical structures rounds out the environment ^[1].

Public reaction has been substantive rather than uniform. Hands-on users on X describe genuinely non-computational workflows - one uploaded a whole-genome VCF file and got back polygenic risk scores after a multi-hour run - and early testers at AI-native biotechs report using it for virtual cell modeling and protein design. But the practitioner community is where the reception turns honestly mixed. Bioinformatics practitioners praised literature review as close to what they found manually, yet flagged weaker performance on extracting structured data from papers and noted how quickly the tool burns through usage limits and tokens. A recurring skeptical refrain - is this just Claude Code with a wrapper? - captures the tension in the orchestration-over-model design, and some noted the bio-only database focus limits neighboring fields. There is also an anxiety thread about AI trained on open-source and community labor being sold back to the practitioners who built it. One biotech R&D user cut what used to take three people two weeks of preliminary research to under an hour, which is the upside case in miniature. The honest read: the literature and synthesis layer is strong today, the data-extraction and cost-control edges are rough, and whether it is a wrapper or a workbench depends largely on how much the orchestration and reproducibility scaffolding is worth to you.